A post-FDA approval development theme for the wound-healing material TDM-511, pursuing expanded indications for severe burns, skin cancer, cosmetic surgery and other applications, as well as combination studies with other drugs, while developing high-value applications through clinical research, partnerships and sales in Europe and the United States.